Philip John Barter, MD, PhD
November 23rd, 2010
How Should We DEFINE Anacetrapib’s Success?
Philip John Barter, MD, PhD and Christopher Paul Cannon, MD
CardioExchange welcomes Philip Barter and Christopher P. Cannon, two of the investigators for the DEFINE trial, which was recently published in the New England Journal of Medicine. Here, they answer questions posed by CardioExchange’s editors. First, some background about the trial: In DEFINE, 1623 patients with or at high risk for coronary disease were randomized to receive […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?